

THE JORDANIAN PHARMACEUTICAL MANUFACTURING CO.

PUBLIC SHAREHOLDING COMPANY

CONSOLIDATED FINANCIAL STATEMENTS

31 DECEMBER 2025

INDEPENDENT AUDITOR'S REPORT

To the Shareholders of The Jordanian Pharmaceutical Manufacturing Company

Public Shareholding Company

Amman – Jordan

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of The Jordanian Pharmaceutical Manufacturing Company - Public Shareholding Company (the "Company") and its subsidiaries (the "Group"), which comprise the consolidated statement of financial position as at 31 December 2025, and the consolidated statement of profit or loss, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects the financial position of the Group as at 31 December 2025, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs).

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards, are further described in the Auditor's Responsibilities for the Audit of the consolidated financial statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the consolidated financial statements in Jordan, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements for the current year. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter provided in that context.

We have fulfilled the responsibilities described in the Auditor's responsibilities for the audit of the consolidated financial statements section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the consolidated financial statements. The results of our audit procedures, including the procedures performed to address the matter below, provide the basis for our audit opinion on the accompanying consolidated financial statements.



1) Revenue Recognition

Disclosures that relate to the revenue recognition are included in Note (20) to the consolidated financial statements. Disclosures that relate to the accounting policies of revenue recognition are included in Note (2-3) to the consolidated financial statements.

Key audit matter

The Group focuses on revenue targets as a key performance measure which may create an incentive for revenue to be recognized before delivering the goods and may result in overstating revenues.

How the key audit matter was addressed in the audit

Our audit procedures included evaluating the Group's revenue recognition accounting policies in accordance with IFRS 15 "Revenue from contracts with customers". We tested the Group's controls over revenue recognition and key controls in the revenue cycle. We also selected a representative sample and tested revenue cutoff date to, assess whether the revenue was recognized in the correct period.

We have also performed detailed analytical procedures for the gross margin on a monthly basis. We also selected and tested a representative sample of journal entries.

2) Property, plant and equipment (Land valuation)

Disclosures that relate to Property, plant and equipment (Land valuation) are included in Note (6) to the consolidated financial statements. Disclosures that relate to the accounting policies of Property, plant and equipment (Land valuation) are included in Note (2-3) to the consolidated financial statements.

Key audit matter

The Group owns lands valued at JOD 7,811,833 under property, plant, and equipment. These assets are measured at fair value, which requires the use of professional estimates and judgment, particularly in the absence of active market prices. Therefore, determining the fair value of the land is subject to significant estimation uncertainty and may be materially affected by changes in external factors such as market conditions and valuation methodologies.

Given the complexity of the valuation process and the importance of land value, we have identified land valuation as a key audit matter.

How the key audit matter was addressed in the audit

1. Evaluation of the valuation methodology: We reviewed the company's valuation methodology and assessed its compliance with International Financial Reporting Standards. We also examined the appropriateness of this methodology to the nature of the land and relevant market conditions.

2. Review of the Independent Valuation Report: We obtained the independent appraiser's report and assessed his qualifications, competence, and impartiality. We also confirmed that the underlying assumptions and inputs used in the valuation were reasonable and consistent with market data available at the report date.

3. Comparison to market data: We compared the fair value of the land with available market data for similar properties in the area, to ensure the valuation was consistent with observable market trends.

Based on these procedures, we concluded that the valuation of the land is reasonable and consistent with applicable accounting standards.



Other Information included in the Group's 2025 annual report

Other information consists of the information included in the annual report, other than the consolidated financial statements and our auditor's report thereon. Management is responsible for the other information. Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with IFRSs, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period, and are therefore the key audit matters. We describe these matters in our auditor's report, unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonable be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

The Group maintains proper books of accounts and the accompanying consolidated financial statements are in agreement therewith. We recommend the general assembly to approve these consolidated financial statements.

The partner in charge of the audit resulting in this auditor's report was Ahmed Mustafa Ramadan; license number 942.

Business Solutions for Auditing

Amman — Jordan

4 March 2026



THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2025

	Note	2025 JD	2024 JD
<u>ASSETS</u>			
Non-current assets -			
Property, plant and equipment	5	17,414,294	17,682,843
Intangible assets	6	2,251,628	2,094,246
Investment in associates	7	5,315,269	4,169,430
Deferred tax assets	25	143,397	991,993
Financial assets at fair value through other comprehensive income	8	392,869	392,869
		<u>25,517,457</u>	<u>25,331,381</u>
Current assets -			
Inventory	9	6,823,222	6,106,184
Other receivables	10	1,238,600	779,593
Due from related parties	11	1,278,915	2,159,804
Accounts receivable	12	8,761,967	12,218,694
Letters of credit under collection		135,393	90,566
Checks under collection		2,544,282	1,534,617
Cash and bank balances	13	1,145,788	49,791
		<u>21,928,167</u>	<u>22,939,249</u>
Total Assets		<u>47,445,624</u>	<u>48,270,630</u>
<u>EQUITY AND LIABILITIES</u>			
Attributable to equity holders of the Parent Company -			
Paid in capital	1	45,416,840	33,698,090
Share discount	1	(32,444,444)	(32,444,444)
Share premium	1	3,187,399	
Statutory reserve	14	709,479	366,777
Cumulative change in fair value of lands		5,489,014	5,489,014
Cumulative change in fair value through other comprehensive income		(2,124,182)	(2,124,182)
Retained earnings		4,338,146	494,162
		<u>24,572,252</u>	<u>5,479,417</u>
Non-controlling interests	26	2,166	144,520
Net Equity		<u>24,574,418</u>	<u>5,623,937</u>
<u>Liabilities</u>			
Non-current liabilities -			
Loans	15	1,221,000	-
Major shareholder loan	16	-	20,659,960
Notes payables	17	2,210,390	3,147,218
		<u>3,431,390</u>	<u>23,807,179</u>
Current liabilities -			
Murabaha financing due within a year	15	5,845,864	977,499
Major shareholder loan due within a year	16	6,301,281	7,000,000
Notes payables due within a year	17	939,312	973,109
Due to related parties	11	1,282,870	1,323,111
Accounts payable		2,812,578	3,706,715
Other payables	18	2,257,911	4,859,080
		<u>19,439,816</u>	<u>18,839,514</u>
Total Liabilities		<u>22,871,206</u>	<u>42,646,693</u>
Total Equity and Liabilities		<u>47,445,624</u>	<u>48,270,630</u>

The accompanying notes from 1 to 33 form integral part of these consolidated financial statements

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
CONSOLIDATED STATEMENT OF PROFIT OR LOSS
FOR THE YEAR ENDED 31 DECEMBER 2025

	Note	2025 JD	2024 JD
Net sales	19	23,562,082	16,864,290
Cost of sales	20	(11,450,823)	(9,140,677)
Gross profit		12,111,259	7,723,613
Selling and distribution expenses	21	(2,558,029)	(2,593,409)
Administrative expenses	22	(3,312,976)	(3,065,856)
Donations		-	(242,676)
Finance costs		(437,891)	(393,095)
Prepayment expenses		(70,786)	(250,116)
Expected credit loss provision	12	-	(6,437)
Groups' share of profit of associates	7	1,145,839	1,508,654
Impairment and amortization of Intangible assets	6	(151,803)	(141,415)
Research and study expenses		(356,214)	(359,315)
Impairment of Inventory provision		-	(200,000)
Medicine registration		(363,156)	(100,342)
Expired goods		(816,569)	(440,696)
Other expenses	23	(443,241)	(607,554)
Other income	24	250,277	148,253
Profit for the year before income tax		4,996,710	979,609
Income tax and national contribution expense for the year	25	(868,324)	(338,643)
Profit for the year		4,128,386	640,966
Profit for the year attributable to:			
Shareholders of the parent company		4,128,386	650,496
Non-controlling interests	27	-	(9,530)
		4,128,386	640,966
		JD/Fils	JD/Fils
Basic and diluted Profit per share for the year attributable to shareholders of the parent company	26	0/126	0/019

The accompanying notes from 1 to 33 form integral part of these consolidated financial statements

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2025

	Note	2025 JD	2024 JD
Profit for the year		4,128,386	650,496
Add: Other comprehensive income items that may not be reclassified to profit or loss in subsequent periods			
Changes in fair value of lands		-	5,489,014
Changes in fair value of financial assets at fair value through other comprehensive income		-	73,450
Total comprehensive income for the year		<u>4,128,386</u>	<u>6,212,960</u>
Total comprehensive income for the year attributable to:			
Shareholders of the parent company		-	6,222,490
Non-controlling interests	27	-	(9,530)
		<u>4,128,386</u>	<u>6,212,960</u>

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025

	Attributable to equity holders of the parent company									
	Paid-in capital	Share discount	Share Premium	Statutory reserve	Cumulative change in fair value of lands	Cumulative change in fair value of financial assets at fair value through other comprehensive income **	Retained earnings *	Total	Non-controlling interests	Net equity
	JD	JD	JD	JD	JD	JD	JD	JD	JD	JD
2025-										
Balance as at 1 January 2025	33,698,090	(32,444,444)	-	366,777	5,489,014	(2,124,182)	494,162	5,479,417	144,520	5,623,937
Profit for the year	-	-	-	-	-	-	4,128,386	4,128,386	-	4,128,386
Other comprehensive income items	-	-	-	-	-	-	-	-	-	-
Total comprehensive income	-	-	-	-	-	-	4,128,386	4,128,386	-	4,128,386
Capital increase (Note 1)	11,718,750	-	3,187,399	-	-	-	-	14,906,149	-	14,906,149
The impact of increase in subsidiaries (Note 2-2)	-	-	-	9,736	-	-	48,564	58,300	(142,354)	(84,054)
Transferred to statutory reserve	-	-	-	332,966	-	-	(332,966)	-	-	-
Balance as at 31 December 2025	45,416,840	(32,444,444)	3,187,399	709,479	5,489,014	(2,124,182)	4,338,146	24,572,252	2,166	24,574,418

* Retained earnings include amounts that cannot be disposed of by the amount of JD 143,397, representing deferred tax assets as of December 31, 2025.

** An amount of JD 2,124,182 cannot be disposed of, representing the negative change in financial assets at fair value through other comprehensive income, in accordance with the instructions of the Jordanian Securities Commission.

FOR THE YEAR ENDED 31 DECEMBER 2025

The impact of the amendments on the subsidiaries (Note 2-2)

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2025

	Note	2025 JD	2024 JD
<u>OPERATING ACTIVITIES</u>			
Profit for the year before income tax		4,996,710	979,609
Adjustments for:			
Depreciation and amortization	5, 6	1,040,193	934,573
Group's share of net profit of associates	7	(1,145,839)	(1,508,654)
Expected credit loss provision	12	-	6,437
Impairment of Inventory provision		-	200,000
Expired goods		816,569	440,104
Finance costs		437,891	393,665
		6,145,524	1,445,734
Changes in working capital -			
Inventories		(1,533,607)	(124,615)
Due from related parties		1,125,040	(639,915)
Accounts receivable		3,068,553	1,391,012
Letters of credit under collection		(44,827)	(90,566)
Checks under collection		(1,009,665)	(869,762)
Other receivables		(459,007)	161,727
Accounts payable		(894,137)	1,259,838
Other payables		(2,601,169)	(106,081)
Net cash flows from operating activities		3,796,705	2,427,372
<u>INVESTING ACTIVITIES</u>			
Purchase of property, plant and equipment	5	(619,841)	(1,445,296)
Purchase of intangible assets	6	(309,185)	(123,608)
Increase in shares of subsidiaries		-	(10,000)
Dividends received	7	-	979,290
Net cash flows used in investing activities		(929,026)	(599,614)
<u>FINANCING ACTIVITIES</u>			
Financing costs paid		(437,891)	(393,665)
Major shareholder loan		(6,452,530)	(2,008,630)
Notes payables		(970,626)	(968,940)
Loans		6,089,365	977,499
Net cash flows used in financing activities		(1,771,682)	(2,393,736)
Net increase (decrease) in cash and cash equivalents		1,095,997	(565,978)
Cash and cash equivalents at the beginning of the year	13	49,791	615,769
Cash and cash equivalents at the end of the year	13	1,145,788	49,791

The accompanying notes from 1 to 33 form integral part of these consolidated financial statements

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(1) GENERAL

The Jordanian Pharmaceutical Manufacturing Company (the "Company") was established on 27 January 2004 as a Public Shareholding Company, as a result of the merger between Al Razi for Pharmaceutical Manufacturing a public shareholding company and the Jordanian Company for the Production of Medicines and Medical Equipment a limited liability company, under registration number 347 with an authorized capital and paid in capital of JD 69,756,944 divided into 69,756,944 shares at par value of JD1 per share.

The company on 18 December 2025 wrote off part of the company's accumulated losses amounting to JD 36,058,854 in the company's capital account, so that the company's capital as of 31 December 2025 became JD 33,698,090 per share with a nominal value of JD1 per share.

The company decided, at the Extraordinary General Assembly meeting held on October 15, 2025, to increase its capital of JOD 33,698,090 by issuing shares with a nominal value of JOD 11,718,750 and a share premium of 0.282 fils per share. As a result, the company's capital became JOD 45,416,840, with a total share premium of JOD 3,187,399. This increase was carried out through the capitalization of part of the balance owed to the main shareholder, Dr. Abdul Jabbar Mohsen Diab Al-Kubaisi, amounting to JOD 15,000,000. All legal procedures related to this increase were completed as of the financial statement date.

The head office of the Company is located in Amman - The Hashemite Kingdom of Jordan.
The Group's main objectives are the production of medical, chemical and pharmaceutical products.
The consolidated financial statements were approved by the Board of Directors on 4 March 2026.

INVESTORS WITH SIGNIFICANT INFLUENCE ON THE GROUP:

Mr. Abdul Jabbar Mohsen Diyab Al-Kubaisi, Mr. Mustafa Ahmed Hamoud Al-Kubaisi, Mr. Yasser Mahmoud Hamid Hamid and Al-Suwar International Investment and Trade Company 48.9%, 19.3%, 10.3% and 7.7% of the company's capital, respectively.

(2-1) BASIS OF PREPARATION

The consolidated financial statements have been prepared on a historical cost basis, except for the financial assets at fair value through other comprehensive income which have been measured at fair value as of the date of the consolidated financial statements.

The consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board ("the Board").

The consolidated financial statements are presented in Jordanian Dinars which is the Company's functional currency.

(2-2) BASIS OF CONSOLIDATION

The consolidated financial statements comprise the financial statements of the Company and its subsidiaries (the "Group") as at 31 December 2025. The subsidiaries that are included in the consolidated financial statements are as follow:

Company Name	Capital (JD)	Main activities	Country of incorporation	Ownership percentage 2025	Ownership percentage 2024
Dellas for Natural Products Co.	150,000	Pharmaceutical industries	Jordan	100%	93.33%
Swagh for Pharmaceutical Manufacturing Co.	150,000	Pharmaceutical industries	Jordan	100%	100%
Aragen for Technical Organic Co.	500,000	Reagent industries	Jordan	100%	100%
Aragen for Technical Organic Co. (Free-Zone)	30,000	Pharmaceutical industries	Jordan	100%	100%
Al Maklafa for Import and Export Co.	10,000	Pharmaceutical marketing	Jordan	51%	51%

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

The control exists when the Group controls the subsidiaries' significant and relevant activities, and is exposed, or has the rights, to variable returns from its involvement with the subsidiaries, and has the ability to affect those returns. Control over the subsidiaries is exercised when the following factors exist:

- Power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee).
- Exposure, or rights, to variable returns from its involvement with the investee.
- The ability to use its power over the investee to affect its returns.

When the Group owns less than a majority of the voting rights in an investee, in this case, the Group considers all factors and circumstances to determine whether it has control over the investee, which include the following:

- Contractual agreements with shareholders that have voting rights in the investee.
- Rights resulting from other contractual arrangements.
- The Group's current and future voting rights in the investee.

The Group reassesses its control over the investee when circumstances and factors exist that lead to the change in one or more of the three factors listed above.

Subsidiaries are fully consolidated from the date of acquisition being the date on which the Group gains control, and continues to do so until the date when such control ceases. The subsidiaries revenues and expenses are consolidated in the consolidated statement of comprehensive income from the date the Group gains control over the subsidiaries until that control ceases.

Profits, losses, and all other comprehensive income items are attributed to the shareholders' equity of the parent company, and to non-controlling interest, even if this leads to a deficit balance. If need arises, the subsidiaries' financial statements are adjusted accordingly to comply with the Group's accounting policies. All intra-group balances, transactions, unrealized gains and losses resulting from intra-group transactions and dividends are eliminated in full.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it:

- Derecognises the assets (including goodwill) and liabilities of the subsidiary
- Derecognises the carrying amount of any non-controlling interest
- Derecognises the cumulative translation differences recorded in equity
- Recognises the fair value of the consideration received
- Recognises the fair value of any investment retained
- Recognises any surplus or deficit in the statement of profit or loss and other comprehensive income
- Reclassifies the parent's share of components previously recognized in OCI to profit or loss or retained earnings, as appropriate, as would be required if the Group had directly disposed of the related assets or liabilities.

(3-1) CHANGES IN ACCOUNTING POLICES

The accounting policies adopted in the preparation of the consolidated financial statements are consistent with those followed in the preparation of the Company's annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of new standards effective as of 1 January 2025:

Lack of exchangeability – Amendments to IAS 21

In August 2023, the IASB issued amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates to specify how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking. The amendments also require disclosure of information that enables users of its financial statements to understand how the currency not being exchangeable into the other currency affects, or is expected to affect, the entity's financial performance, financial position and cash flows.

The amendments had no impact on the Group's consolidated financial statements.

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(3-2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounts receivable

Trade receivables are measured at the transaction price determined under IFRS 15. The Group recognises an allowance for expected credit losses (ECLs) for trade receivables. The Group applies a simplified approach in calculating ECLs. The Group recognises a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

Property, plant and equipment

Property, plant and equipment are stated at cost, net of accumulated depreciation and any impairment value. When assets are sold or retired, their cost and accumulated depreciation are eliminated from the accounts and any gain or loss resulting from their disposal is included in the consolidated statement of profit or loss.

Depreciation (except for lands) is computed on a straight-line basis over the estimated useful lives of assets at the following annual rates:

	<u>%</u>
Buildings	2-4
Machinery and equipment	5-10
Tools and equipment	10-25
Vehicles	10
Furniture and fixtures	10

When the carrying values exceed the estimated recoverable amounts of the property, plant and equipment, the assets are written down to their recoverable amounts of the property, plant and equipment, and the impairment is recorded in the consolidated statement of profit or loss.

The useful life and depreciation method are reviewed periodically to ensure that the method and period of depreciation are consistent with the expected pattern of economic benefits from items of property, plant and equipment.

Intangible assets

The measurement of intangible assets at acquisition by cost or fair value if resulting from the acquisition of subsidiaries.

The useful lives of intangible assets are assessed as either finite or indefinite. Finite intangible assets are amortized over their useful lives and recorded in the consolidated statement of profit and loss. Indefinite intangible assets are tested for impairment on an annual basis and recorded in the consolidated statement of profit and loss.

Internally generated intangibles from the operations of the group are not capitalised and the related expenditure is reflected in the consolidated statement of profit or loss in the period in which the expenditure is incurred.

Intangible assets are reviewed for indications of impairment on the date of the consolidated financial statements. In addition, the useful life of these assets are reviewed where the adjustments are made on the subsequent years.

Intangible assets are amortized over the expected useful life using the following annual ratios:

	<u>%</u>
Bio-equivalent studies	Indefinite useful life
Patent	Indefinite useful life
Medicine registration	20

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

Investments in associates

Associates are entities in which the Group has significant influence and which is neither a subsidiary nor a joint venture. The Group's investments in its associates are accounted for using the equity method.

The investments in associates are carried in the consolidated statement of financial position at cost plus post acquisition changes in the Group's share of net assets of the associate. Goodwill relating to an associate is included in the carrying amount of the investment account in associate company and is not amortized. The consolidated statement of profit or loss reflects the share of the results of operations of the associate. Where there has been a change recognized directly in the equity of the associate, the Group recognizes its share of any changes and discloses this, when applicable, in the consolidated statement of changes in equity. Unrealized gains and losses resulting from transactions between the Group and the associate are eliminated to the extent of the interest in the associates.

Financial assets at fair value through other comprehensive income

Financial assets at fair value through other comprehensive income are recorded at fair value when purchased plus acquisition costs and subsequently measured at fair value. Changes in fair value are reported as a separate component in the consolidated statement of comprehensive income and in the consolidated statement of equity including the change in fair value resulting from conversion differences of non-cash items of assets at foreign currencies. In case of sale of such assets or part of it, the gain or loss is recorded at the consolidated statement of comprehensive income and in the consolidated statement of changes in equity and the valuation reserve balance for sold assets will be transferred directly to retained earnings not through the consolidated statement of profit or loss.

These assets are not subject to impairment testing. Dividends are recognized in the consolidated statement of profit or loss.

Inventories

Inventories are valued at the lower of cost and net realizable value.

Net realizable value represents the estimated selling price for inventories less all estimated costs of completion and costs necessary to make the sale.

Cost is calculated as follows:

Raw materials: purchase cost is determined on the weighted average basis.

Finished goods and work in progress: cost of direct materials and a proportion of manufacturing overheads using is determined on the weighted average basis.

Cash and cash equivalents

Cash and cash equivalents include cash on hand and at banks with original maturities of three months or less with no risk of change in their value.

For the purpose of the preparation of consolidated statement of cash flows, cash and cash equivalents consists of cash and short-term deposits are defined above, net of outstanding bank overdraft and restricted cash.

Provisions

Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the statement of profit or loss net of any reimbursement.

Fair value

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible to by the Group.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 - Quoted (unadjusted) market prices in active markets for identical assets or liabilities.
- Level 2 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.
- Level 3 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognized in the consolidated financial statements, the Group determines, whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level of input that is considered essential to the fair value measurement as a whole) at the end of each reporting period.

Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

Loans

After initial recognition, loans are subsequently measured at amortised cost using the effective interest rate method. Gains and losses are recognised in consolidated statement of profit or loss when the liabilities are derecognised as well as through effective interest amortisation process. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest. The effective interest amortisation is included in finance costs in the consolidated statement of profit and loss.

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

Accounts payables

Liabilities are recognized for amounts to be paid in the future for services or goods received whether billed by the supplier or not.

Income tax

Current income tax is calculated in accordance with the Income Tax Laws in Jordan and the countries where the subsidiaries operate.

Tax expense comprises current tax and deferred taxes.

Current tax is calculated based on taxable profits, which may differ from accounting profits appearing in the consolidated financial statements. Accounting profits may include non-taxable profits or expenses which may not be tax deductible in the current but in subsequent applicable years or taxable accumulated losses or non taxable nor deductible items.

Deferred income tax is provided using the liability method on temporary differences at the consolidated financial statements date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. Deferred income tax is measured at the tax rates that are expected to apply to the year when the tax liability is settled or the tax asset is realized.

The carrying amount of deferred income tax assets is reviewed at each consolidated financial statement date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized.

Foreign currencies

The consolidated financial statements are presented in Jordanian Dinars, which is the parent's functional and presentation currency. Each subsidiary determines its own functional currency.

Transactions in foreign currencies are initially recorded in the functional currency rate ruling at the date transaction. Monetary assets and liabilities dominated in foreign currency are retranslated at the functional currency rate of exchange ruling at the statement of financial position date. Profit or loss resulting from transactions in foreign currencies are recorded in the consolidated statement of profit and loss.

Assets and liabilities of subsidiaries that have functional currencies different from the presentation currency of the Parent are translated at the rate of exchange ruling at the consolidated statement of financial position date. Revenues and expenses of those subsidiaries are translated using the average exchange rate for the year. All resulting exchange differences are recorded as a separate component of equity.

Offsetting

Financial assets and financial liabilities are only offset and the net amount reported in the consolidated statement of financial position when there is a legally enforceable right to set off the recognized amounts and the Group intends to either settle on a net basis, or to realize the asset and settle the liability simultaneously.

Revenue

Revenue from contracts with customers

Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Group has generally concluded that it is the principal in its revenue arrangements, because it typically controls the goods or services before transferring them to the customer.

Variable consideration

If the consideration in a contract includes a variable amount, the Group estimates the amount of consideration to which it will be entitled in exchange for transferring the goods to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty with the variable consideration is subsequently resolved. Some contracts provide customers with a right of return. The rights of return give rise to variable consideration.

Rights of return

Certain contracts provide a customer with a right to return the goods within a specified period. The Group uses the expected value method to estimate the goods that will not be returned because this method best predicts the amount of variable consideration to which the Group will be entitled. The requirements in IFRS 15 on constraining estimates of variable consideration are also applied in order to determine the amount of variable consideration that can be included in the transaction price. For goods that are expected to be returned, instead of revenue, the Group recognizes a refund liability.

Refund liabilities

A refund liability is the obligation to refund some or all of the consideration received (or receivable) from the customer and is measured at the amount the Group ultimately expects it will have to return to the customer. The Group updates its estimates of refund liabilities (and the corresponding change in the transaction price) at the end of each reporting period. Refer to above accounting policy on variable consideration.

Interest income is recognized using the effective interest rate method

Other revenues are recognized on the accrual basis.

(4) SIGNIFICANT ACCOUNTING ESTIMATES

The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of financial assets and liabilities and disclosure of contingent liabilities. These estimates and assumptions also affect the revenues and expenses and the provisions. In particular, considerable judgment by management is required in the estimation of the amount and timing of future cash flows when determining the level of provisions required in the future. Such estimates are necessarily based on assumptions about several factors involving varying degrees of judgment and uncertainty and actual results may differ resulting in future changes in such provisions.

Judgments, estimates and assumptions in the consolidated financial statements are detailed below:

- The Group uses a provision matrix to calculate ECLs for trade receivables. The provision rates are based on days past due for groupings of various customer segments that have similar loss Letters (i.e., by geography, product type, customer type and rating, and coverage by letters of credit and other forms of credit insurance).

The provision matrix is initially based on the Group's historical observed default rates. The Group will calibrate the matrix to adjust the historical credit loss experience with forward-looking information. For instance, if forecast economic conditions (i.e., gross domestic product) are expected to deteriorate over the next year which can lead to an increased number of defaults in the pharmaceuticals sector, the historical default rates are adjusted. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed.

The assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate. The amount of ECLs is sensitive to changes in circumstances and of forecast economic conditions. The Group's historical credit loss experience and forecast of economic conditions may also not be representative of customer's actual default in the future.

- Income tax expense is calculated and charged for the year in accordance with laws and regulation and IAS.
- Certain contracts for the sale of goods include a right of return that give rise to variable consideration. In estimating the variable consideration, the Group is required to use either the expected value method or the most likely amount method based on which method better predicts the amount of consideration to which it will be entitled.

The Group determined that the expected value method is the appropriate method to use in estimating the variable consideration for the sale of goods with rights of return, given the large number of customer contracts that have similar characteristics.

Before including any amount of variable consideration in the transaction price, the Group considers whether the amount of variable consideration is constrained. The Group determined that the estimates of variable consideration are not constrained based on its historical experience, business forecast and the current economic conditions. In addition, the uncertainty on the variable consideration will be resolved within a short time frame.

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(5) <u>PROPERTY, PLANT AND EQUIPMENT</u>									
	Land	Buildings	Machinery and equipment	Tools	Vehicles	Furniture	Total		
	JD	JD	JD	JD	JD	JD	JD		
2025 - Cost-									
Balance as at 1 January 2025	7,811,833	11,500,064	13,347,317	3,652,884	351,359	813,405	37,476,862		
Additions	-	49,522	278,178	273,910	-	18,231	619,841		
Balance as at 31 December 2025	7,811,833	11,549,586	13,625,794	3,926,794	351,359	831,636	38,096,703		
Accumulated Depreciation -									
Balance as at 1 January 2025	-	5,201,971	10,496,275	3,068,363	283,274	744,136	19,794,019		
Depreciation charge for the year	-	315,033	451,824	102,360	9,180	9,993	888,390		
Balance as at 31 December 2025	-	5,517,004	10,948,099	3,170,723	292,454	754,129	20,682,409		
Net book value -									
As at 31 December 2025	7,811,833	6,032,582	2,677,396	756,071	58,905	77,507	17,414,294		
2024 - Cost-									
Balance as at 1 January 2024	490,127	3,962,819	12,260,027	3,523,062	351,359	789,351	21,340,745		
Additions	-	204,130	1,087,290	129,822	-	24,054	1,445,296		
Transfer from Right of use assets	1,832,692	7,369,115	-	-	-	-	9,201,807		
Land revaluation differences	5,489,014	-	-	-	-	-	5,489,014		
Balance as at 31 December 2024	7,811,833	11,500,064	13,347,317	3,652,884	351,359	813,405	37,476,862		
Accumulated Depreciation -									
Balance as at 1 January 2024	-	2,921,298	10,137,335	2,959,406	274,094	735,801	17,027,934		
Depreciation charge for the year	-	307,746	358,940	108,957	9,180	8,355	793,158		
Transfer from Right of use assets	-	1,972,927	-	-	-	-	1,972,927		
Balance as at 1 January 2024	-	5,201,971	10,496,275	3,068,363	283,274	744,136	19,794,019		
Net book value -									
As at 31 December 2024	7,811,833	6,298,093	2,851,042	584,521	68,085	69,269	17,682,843		

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

Depreciation expense is distributed in the consolidated statement of profit or loss as follows:

	2025	2024
	JD	JD
Cost of sales (Note 20)	851,776	792,487
Selling and distribution expenses (Note 21)	4,463	101
Administrative expenses (Note 22)	32,151	570
	<u>888,390</u>	<u>793,158</u>

(6) INTANGIBLE ASSETS

	Bio-equivalent studies	Patent	Medicine registration	Total
	JD	JD	JD	JD
2025 -				
Cost-				
Balance as at 1 January	5,628,359	3,880,133	1,675,979	11,184,471
Additions	181,907	-	127,278	309,185
Balance as at 31 December	<u>5,810,266</u>	<u>3,880,133</u>	<u>1,803,257</u>	<u>11,493,656</u>
Amortization Depreciation -				
As at 1 January	3,690,597	3,868,065	1,531,563	9,090,225
Amortization charge for the year	-	-	61,902	61,902
Impairment losses *	78,369	11,532	-	89,901
As at 31 December	<u>3,768,966</u>	<u>3,879,597</u>	<u>1,593,465</u>	<u>9,242,028</u>
Net book value as at 31 December	<u>2,041,300</u>	<u>536</u>	<u>209,792</u>	<u>2,251,628</u>
2024 -				
Cost-				
Balance as at 1 January	5,576,609	3,880,133	1,609,105	11,065,847
Additions	56,734	-	66,874	123,608
Disposal	(4,984)	-	-	(4,984)
Balance as at 31 December	<u>5,628,359</u>	<u>3,880,133</u>	<u>1,675,979</u>	<u>11,184,471</u>
Amortization Depreciation -				
As at 1 January	3,627,777	3,856,533	1,469,484	8,953,794
Amortization charge for the year	-	-	62,079	62,079
Impairment losses *	67,804	11,532	-	79,336
Disposal	(4,984)	-	-	(4,984)
As at 31 December	<u>3,690,597</u>	<u>3,868,065</u>	<u>1,531,563</u>	<u>9,090,225</u>
Net book value as at 31 December	<u>1,937,762</u>	<u>12,068</u>	<u>144,416</u>	<u>2,094,246</u>

* On 31 December 2025, the Group performed an impairment test on the Bio-equivalence studies and Patents value (intangible assets with indefinite useful life) by calculating their fair value. based on the results impairment loss was recognized by the amount of JD 89,901 during the year 2025.

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(7) INVESTMENT IN AN ASSOCIATE

	Country of Incorporation	Activity	Ownership interest		2025	2024
			2025	2024	JD	JD
Azal Pharmaceutical Company	Eritrea	Pharmaceutical industries	42%	42%	5,295,543	4,149,704
Jordan Algerian Pharmaceutical Manufacturing Co.	Algeria	Pharmaceutical industries	49%	49%	19,726	19,726
					<u>5,315,269</u>	<u>4,169,430</u>

Movement on investments in associates is as follows:

	2025	2024
	JD	JD
Balance beginning of the year	4,169,430	3,640,066
Group's share of Associates' net results current year	1,145,839	841,039
Group's share of Associates' net results previous years	-	667,615
Distribution of Dividends of Azel Pharmaceutical Company	-	(979,290)
Balance ending of the year	<u>5,315,269</u>	<u>4,169,430</u>

The following table summarize of the financial information of the group's investment in its associate:

	2025		
	Azal Pharmaceutical Company	Jordan Algerian Pharmaceutical Manufacturing Co.	Total
	JD	JD	JD
<u>The company's share of net equity:</u>			
Current assets	18,752,325	1,632,696	20,385,021
Non- current assets	1,225,962	2,063	1,228,025
Current liabilities	(6,988,114)	(1,594,502)	(8,582,616)
Non- Current liabilities	(381,738)	-	(381,738)
Net Equity	<u>12,608,435</u>	<u>40,257</u>	<u>12,648,692</u>
Percentage of ownership	42%	49%	
Group's share in net equity	5,295,543	19,726	5,315,269
Net investment as at 31 December	<u>5,295,543</u>	<u>19,726</u>	<u>5,315,269</u>

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

	2024		
	Azal Pharmaceutical Company	Jordan Algerian Pharmaceutical Manufacturing Co.	Total
	JD	JD	JD
<u>The company's share of net equity:</u>			
Current assets	15,150,594	1,632,696	16,783,290
Non- current assets	1,172,355	2,063	1,174,418
Current liabilities	(6,061,029)	(1,594,502)	(7,655,531)
Non- Current liabilities	(381,673)	-	(381,673)
Net Equity	9,880,247	40,257	9,920,504
Percentage of ownership	42%	49%	
Group's share in net equity	4,149,704	19,726	4,169,430
Net investment as at 31 December	4,149,704	19,726	4,169,430

(8) FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

	Country	2025	2024
		JD	JD
<u>Stocks of companies not listed</u>			
Arab Company for Drug Industries	Tunis	392,867	392,867
Tasili Takafo Company	Algeria	1	1
Egyptian Obour Company	Egypt	1	1
		392,869	392,869

(9) INVENTORY

	2025	2024
	JD	JD
Raw materials	2,768,891	2,446,638
Finished goods	2,515,227	2,305,899
Packing materials	1,069,493	961,397
Spare parts and other consumables	469,611	392,250
	6,823,222	6,106,184

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(10) OTHER RECEIVABLES

	2025	2024
	JD	JD
Prepaid expenses	578,773	297,301
Sales tax deposit	166,325	132,341
Projects in progress	137,574	-
Refundable deposits	107,785	35,869
Guarantee margin	75,654	190,618
Income tax deposit	61,802	22,567
Employee Receivables	23,663	50,524
Other	87,024	50,373
	<u>1,238,600</u>	<u>779,593</u>

(11) RELATED PARTIES BALANCES AND TRANSACTIONS

Related parties represent major shareholders, directors and key management personnel of the Company, associates Company's and entities significantly controlled by them. Pricing policies and terms of the transactions are approved by the Group management.

Balances with related parties as shown in the consolidated statement of financial position are as follows:

	Nature of relationship	2025	2024
		JD	JD
Amounts due from related parties:			
Jordan Algerian Pharmaceutical Manufacturing Co.	Associate Company	1,278,915	1,182,968
Azal Pharmaceutical Company	Associate Company	-	976,836
		<u>1,278,915</u>	<u>2,159,804</u>
Amounts due to related parties:			
Jordan Algerian Pharmaceutical Manufacturing Co.	Associate Company	691,509	983,736
Azal Pharmaceutical Company	Associate Company	2,455	-
Dr. Adnan Ali Hussein Badwan	BOD Member	588,906	339,375
		<u>1,282,870</u>	<u>1,323,111</u>
Major shareholder loan			
Mr. Abdul Jabbar Mohsen Diyab Al-Kubaisi	Major Shareholder	<u>6,301,281</u>	<u>27,659,960</u>
Other payables:			
Amounts due to the Board of Directors	Board Members	<u>187,622</u>	<u>195,729</u>

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

The following is a summary of transactions with related parties that appear in the consolidated statement of profit or loss:

	Nature of relationship	2025 JD	2024 JD
Administrative expenses:			
Board members transportation	Board Members	64,980	66,517
Other expenses:			
Dr. Adnan Ali Hussein Badwan	BOD Member	421,962	339,375

Short term salaries, transportation and other benefits of key management personnel amounted to JD 507,251 for the year ended 31 December 2025 (for the year ended 31 December 2024: JD 478,623).

(12) ACCOUNTS RECEIVABLE

	2025 JD	2024 JD
Local Receivables	4,187,728	7,694,811
Foreign Receivables	20,147,812	20,119,580
	24,335,540	27,814,391
Expected credit loss provision*	(15,573,573)	(15,595,697)
	8,761,967	12,218,694

The following is the accounts receivable ageing as of December 31 using expected credit loss provision matrix:

	Weighted average loss rate	Accounts receivables JD	Expected credit loss allowance JD
2025-			
Less than 90 days	6.5%	3,347,082	220,073
91 - 180 days	10%	2,662,438	266,244
181 - 270 days	15%	853,927	128,089
271 - 365 days	20%	1,449,832	290,716
365 - 730 days	50%	2,707,620	1,353,810
More than 730	100%	13,314,641	13,314,641
		24,335,540	15,375,573
2024-			
Less than 90 days	4.6%	5,911,541	271,864
91 - 180 days	10%	3,563,542	356,354
181 - 270 days	15%	1,050,468	157,570
271 - 365 days	20%	1,620,868	325,874
365 - 730 days	50%	2,367,874	1,183,937
More than 730	100%	13,300,098	13,300,098
		27,814,391	15,595,697

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

* The movement on the expected credit losses provision is as follows:

	2025	2024
	JD	JD
As at 1 January	15,595,697	15,589,260
Charge for the year	-	6,437
Used during the year	(22,124)	-
As at 31 December	15,573,573	15,595,697

Based on the Group's management estimates receivables are expected to be fully recoverable. The Group does not obtain any guarantees against these receivables.

(13) CASH AND CASH EQUIVALENTS

	2025	2024
	JD	JD
Portfolio deposits	7,500	7,500
Bank balances	1,127,480	33,527
Cash on hand	10,808	8,764
Cash and bank balances	1,145,788	49,791

(14) EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE PARENT

Paid in capital and share discount–

The company decided, at the Extraordinary General Assembly meeting held on October 15, 2025, to increase its capital of JOD 33,698,090 by issuing shares with a nominal value of JOD 11,718,750 and a share premium of 0.282 fils per share. As a result, the company's capital became JOD 45,416,840, with a total share premium of JOD 3,187,399. This increase was carried out through the capitalization of part of the balance owed to the main shareholder, Dr. Abdul Jabbar Mohsen Diab Al-Kubaisi, amounting to JOD 15,000,000.

Statutory reserve -

The accumulated balances in this account represent 10% of the pretax income transferred to statutory reserve. Moreover, transfers might be stopped when the statutory reserve reaches 25% of the Company's paid-in capital unless the general assembly approves to continue to build the reserve using the same rate until it equals its paid in capital. This reserve is not available for distribution to the shareholders.

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(15) MURABAHA FINANCING

	Currency	2025			2024		
		Payable within one year	Long-term	Total	Payable within one year	Long-term	Total
		JD	JD	JD	JD	JD	JD
Commercial Bank Loan	JOD	3,556,009	1,221,000	4,777,009	-	-	-
Bank of Jordan Loan	JOD	2,289,855	-	2,289,855	-	-	-
Union Bank Loan	JOD	-	-	-	977,499	-	977,499
		<u>5,845,864</u>	<u>1,221,000</u>	<u>7,066,864</u>	<u>977,499</u>	<u>-</u>	<u>977,499</u>

Commercial Bank Loan –

The company obtained loans from the Jordan Commercial Bank. During 2025, an agreement was signed and banking facilities were secured, including a revolving short-term loan of JOD 3.3 million at an annual interest rate of 9.5%, which was later reduced to 9%. This facility is used to finance the company's purchases of local and imported raw materials. In addition, an overdraft facility of JOD 200,000 was granted, renewable annually, with an interest rate of 9.5%, later reduced to 9%.

The company also obtained approval for and received a long-term loan (asset loan) supported by the Central Bank, amounting to JOD 1.5 million, with an interest rate of 3.5%, later reduced to 3.25%. This loan includes a grace period of 12 months, followed by repayment over a period of 48 months.

Bank of Jordan Loan –

An agreement was reached and signed with Bank of Jordan to grant a short-term revolving credit facility for financing local sales (cheque discounting), amounting to JOD 3 million, at an interest rate of 9%.

The principal installments payable during next years are as follow:

YEAR	JD
2027	372,000
2028	372,000
2029	372,000
2030	372,000
	<u>1,221,000</u>

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(16) MAJOR SHAREHOLDER LOAN

Based on the decision of the company's board of directors Company approved the transfer of the full net direct debt owed to the Jordan Islamic Bank, amounting to JOD 29,668,590, in favor of Mr. Abdul Jabbar Mohsen Diyab Al-Kubaisi. This transfer was executed pursuant to the Share Sale and Assignment of Rights Agreement signed between the Jordan Islamic Bank and the second party comprising Mr. Mustafa Ahmad Hamoud Al-Kubaisi, Mr. Abdul Jabbar Mohsen Diyab Al-Kubaisi, Mr. Yasser Mahmoud Hameed Hameed, and Al-Sewar International Investment and Trading Company.

	2025 JD	2024 JD
Balance as at 1 January	27,659,960	-
Net direct debt transferred from the Jordan Islamic Bank	-	29,668,590
Paid within a year	(6,452,530)	(2,008,630)
Used to increase capital	(14,906,149)	-
	<u>6,301,281</u>	<u>27,659,960</u>
Due within a year	6,301,281	7,000,000
Due within more one year	-	27,659,960
Balance as at 31 December	<u>6,301,281</u>	<u>27,659,960</u>

(17) NOTE PAYABLES

		2025			2024		
	Currency	Payable within one year			Payable within one year		
		year	Long-term	Total	year	Long-term	Total
		JD	JD	JD	JD	JD	JD
Income and sales tax	JOD	351,096	1,404,624	1,755,720	351,084	1,755,780	2,106,864
Social security 1	JOD	173,152	684,972	858,124	171,461	855,581	1,027,042
Social security 2	JOD	24,564	120,794	145,358	24,564	145,358	169,922
Al Noor Drug Store Company	JOD	390,500	-	390,500	426,000	390,500	816,500
		<u>939,312</u>	<u>2,210,390</u>	<u>3,149,702</u>	<u>973,109</u>	<u>3,147,219</u>	<u>4,120,328</u>

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

NOTES PAYABLES - INCOME AND SALES TAX

During 2020, the Company scheduled its outstanding obligations to the Income and Sales Tax Department over 10 years, 120 installments, the first installment was due on 20 January 2024, and the last installment is due on 20 December 2030.

NOTES PAYABLES - SOCIAL SECURITY 1

During 2020, the Company scheduled its outstanding obligations to the Social Security Corporation over 10 years, 120 installments, the first installment was due on 2 December 2020, and the last installment is due on 2 November 2030.

NOTES PAYABLES - SOCIAL SECURITY 2

During 2021, Aragne Biotechnology Company (a subsidiary) has scheduled its outstanding commitments to the Social Security Corporation over 10 years, 120 installments, the first installment is due on 4 December 2024, and the last installment is due on 4 November 2031.

NOTES PAYABLES - AL NOOR DRUG STORE COMPANY

During 2021, settlement agreement was signed with Al Noor Drugstore (the company's former agent in the United Arab Emirates), according to this settlement JD 710,000 out of JD 2,840,000 was paid, and the remaining balance was scheduled over five years.

The principal installments payable during next years are as follow:

<u>YEAR</u>	<u>JD</u>
2027	679,663
2028	648,059
2029	616,455
2030	568,935
2031	22,538
	<u>2,535,650</u>
Less: Deferred finance cost	<u>(325,260)</u>
	<u><u>2,210,390</u></u>

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(18) OTHER PAYABLES

	<u>2025</u>	<u>2024</u>
	JD	JD
Accrued expenses	1,194,397	1,636,042
Employee payable	198,522	1,145,702
Shareholders' deposit	328,066	1,019,614
Postdated checks	112,167	456,623
Board of directors payables	186,992	195,729
Provision for staff indemnity	108,179	146,682
Sales tax payable	75,951	73,155
Income tax payable	1,491	1,616
Other	52,146	183,917
	<u>2,257,911</u>	<u>4,859,080</u>

(19) NET SALES

	<u>2025</u>	<u>2024</u>
	JD	JD
Local sales	8,279,253	9,292,438
Export sales	15,282,829	7,571,852
	<u>23,562,082</u>	<u>16,864,290</u>

Revenues are generated from sale of pharmaceutical products in the local and external markets, where the revenue is recognized at a point in time when the goods are transferred to the customer (when completing the performance obligation).

(20) COST OF GOODS SOLD

	<u>2025</u>	<u>2024</u>
	JD	JD
Raw materials used in production	5,772,184	4,049,834
Salaries, wages and other benefits	3,512,294	3,030,498
Electricity and water	606,576	512,184
Depreciation of property, plant and equipment (note 5)	851,776	792,487
Transportation and travel	214,644	243,743
Maintenance	200,444	258,804
Other manufacturing expenses	292,905	253,127
	<u>11,450,823</u>	<u>9,140,677</u>

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(21) SELLING AND MARKETING EXPENSE

	2025	2024
	JD	JD
Salaries, wages and other benefit	1,204,754	1,372,422
Expenses to support foreign markets	335,418	286,242
Export and shipping	470,117	337,115
Samples	103,687	130,967
Advertising	250,052	235,751
Rent	27,153	40,514
Depreciation of property, plant and equipment (note 6)	4,463	101
Other	162,385	190,297
	<u>2,558,029</u>	<u>2,593,409</u>

(22) ADMINISTRATIVE EXPENSE

	2025	2024
	JD	JD
Salaries, wages and other benefits	2,294,688	2,032,781
Legal and Lawyer fees	425,981	680,911
Remunerations of Board of Directors	64,980	66,517
Computers	80,212	63,601
Fines and penalties	23,095	24,780
Hospitality and cleaning	99,800	28,459
Depreciation of property, plant and equipment (note 6)	32,151	570
Telephone and post	19,923	12,035
Other	272,146	156,202
	<u>3,312,976</u>	<u>3,065,856</u>

(23) OTHER EXPENSES

	2025	2024
	JD	JD
Collection commission expense	421,962	607,554
Foreign currency losses	21,279	-
	<u>443,241</u>	<u>607,554</u>

(24) OTHER INCOME

	2025	2024
	JD	JD
Sale of empty boxes	17,834	5,578
Other income	232,443	142,675
	<u>250,277</u>	<u>148,253</u>

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(25) INCOME TAX

A- INCOME TAX EXPENSE

The details of income tax expense is the statement of comprehensive income is as follows:

	2025	2024
	JD	JD
National contribution expense for the year	(52,754)	(9,011)
Income tax expense for the year	(1,055,092)	(90,110)
Deferred tax assets	239,522	(239,522)
	<u>(868,324)</u>	<u>(338,643)</u>

B- DEFERRED TAX ASSETS

	Statement of Financial Position		Statement of Comprehensive Income		Statement of changes in Equity	
	2025	2024	2025	2024	2025	2024
	JD	JD	JD	JD	JD	JD
Deferred Tax assets from accumulated losses	143,397	991,993	-	-	-	-

The Jordanian Pharmaceutical Manufacturing Company

Income tax provision was calculated for the year ended 31 December 2025 by the amount of JOD 1,053,849 due to the excess of taxable revenues over deductible expenses in accordance with the income tax law no. (38) for the year 2018.

The Company obtained a final clearance from the Income Tax Department until the end of 2020. The Company has also submitted 2021, 2022, 2023 and 2024 income tax return to the Income and Sales Tax Department within the legal timeframe.

Dellas for Natural Products Company-

Income tax provision was calculated for the year ended 31 December 2025 by the amount of JOD 53,997 due to the excess of taxable revenues over deductible expenses in accordance with the income tax law no. (38) for the year 2018.

The Company obtained a final clearance from the Income Tax Department until the end of 2021. The Company has also submitted 2022, 2023 and 2024 income tax returns to the Income and Sales Tax Department within the legal timeframe.

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

Aragen for Technical Organic Company and its subsidiary-

No income tax provision was calculated for the years ended 31 December 2025 due to the excess of deductible expenses over taxable revenues in accordance with the income tax law no. (38) for the year 2018.

The Company obtained a final clearance from the Income Tax Department until the end of 2023. The Company has also submitted 2024 income tax return to the Income and Sales Tax Department within the legal timeframe.

Swagh for Pharmaceutical Manufacturing Company-

No income tax provision was calculated for the years ended 31 December 2025 due to the excess of deductible expenses over taxable revenues in accordance with the income tax law no. (38) for the year 2018.

The Company obtained a final clearance from the Income Tax Department until the end of 2022. The Company has also submitted 2023 and 2024 income tax returns to the Income and Sales Tax Department within the legal timeframe.

Al Maklafa for Import and Export Company-

No income tax provision was calculated for the years ended 31 December 2025 due to the excess of deductible expenses over taxable revenues in accordance with the income tax law no. (38) for the year 2018.

The Company obtained a final clearance from the Income Tax Department until the end of 2023. The Company has also submitted 2024 income tax returns to the Income and Sales Tax Department within the legal timeframe.

(26) BASIC AND DILUTED PROFIT PER SHARE FOR THE YEAR

	<u>2025</u>	<u>2024</u>
	JD	JD
Profit for the year attributable to shareholders of the parent company	4,128,386	650,496
Weighted average number of shares (share)	33,698,090	33,698,090
	<u>JD/Fils</u>	<u>JD/Fils</u>
Basic and diluted profit per share for the year attributable to shareholders of the parent company	0/126	0/019

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(27) MATERIAL PARTIALLY OWNED SUBSIDIARIES BY THE GROUP

Proportion of equity interest held by non-controlling interests:

Company Name	Main activities	Country of incorporation	Country of incorporation 2025	Country of incorporation 2024
Dellas for Natural Products Co.	Pharmaceutical industries	Jordan	-	6,66%
Al Maklafa for Import and Export Co.	Pharmaceutical marketing	Jordan	49%	49%

Accumulated balance of non-controlling interests is as follows:

	2025	2024
	JD	JD
Dellas for Natural Products Co.	-	142,354
Al Maklafa for Import and Export Co.	2,166	2,166
	<u>2,166</u>	<u>144,520</u>

The share of rights of non-controllers from the comprehensive income is as follows:

	2025	2024
	JD	JD
Dellas for Natural Products Co.	-	(6,928)
Al Maklafa for Import and Export Co.	-	(2,602)
Total	<u>-</u>	<u>(9,530)</u>

Below is a summary of the financial information for the subsidiaries (before the elimination of the intercompany transactions and balances with subsidiaries):

Summarized statement of comprehensive income for year 2025:

	Al Maklafa for Import and Export Co.	Total
	JD	JD
Net sales	-	-
Cost of goods sold	-	-
Selling and distribution expense	-	-
Administrative expense	-	-
other expenses	-	-
loss for the year	<u>-</u>	<u>-</u>
Other comprehensive income	-	-
Total comprehensive income	<u>-</u>	<u>-</u>
Non-controlling interests	<u>-</u>	<u>-</u>

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

Summarized statement of financial position as at 31 December 2025:

	Al Maklafa for Import and Export Co.	Total
	JD	JD
Current assets	9,900	9,900
Non-current assets	-	-
Current liabilities	(5,480)	(5,480)
Non-current liabilities	-	-
Total equity	4,420	4,420
Non-controlling interests	2,166	2,166

Summarized statement of comprehensive income for the year 2024:

	Dellas for Natural Products Co.	Al Maklafa for Import and Export Co.	Total
	JD	JD	JD
Net sales	1,238,776	-	1,238,776
Cost of goods sold	(679,161)	-	(679,161)
Selling and distribution expense	(362,275)	-	(362,275)
Administrative expense	(184,762)	(5,310)	(190,072)
other expenses	(116,499)	-	(116,499)
loss for the year	(103,921)	(5,310)	(109,231)
Other comprehensive income	-	-	-
Total comprehensive income	(103,921)	(5,310)	(109,231)
Non-controlling interests	(6,928)	(2,602)	(9,530)

Summarized statement of financial position as at 31 December 2024:

	Dellas for Natural Products Co.	Al Maklafa for Import and Export Co.	Total
	JD	JD	JD
Current assets	2,958,036	9,900	2,967,936
Non-current assets	338,717	-	338,717
Current liabilities	(1,161,445)	(5,480)	(1,166,925)
Non-current liabilities	-	-	-
Total equity	2,135,308	4,420	2,139,728
Non-controlling interests	142,354	2,166	144,520

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(28) RISK MANAGEMENT

- Interest rate risk

Interest rate risk is the risk that the fair value of future cash flow of a financial instrument will fluctuate because of changes in market interest rate. The Group's exposed to interest rate risk on its financial assets and liability that carry interest such as Deposits Overdraft and Murabaha .

The sensitivity of the consolidated statement of profit or loss is the effect of the assumed changes in interest rates on the Group's profit for one year, based on the floating rate financial assets and financial liabilities held at 31 December 2025 and 2024.

Credit risk -

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The group is exposed to credit risk through its operational activities (accounts receivable) and financing activities (Deposits at banks) and other financial instruments included in the consolidated statement of financial position.

The Group seeks to limit its credit risk with respect to customers by monitoring outstanding receivables and with respect to banks by only dealing with reputable banks.

The group sells its products to a large number of customers, and this represents the largest 10 customers with 35% of the receivables as of December 31, 2025 (2024: the largest 10 customers with 40%.)

Liquidity risk -

Liquidity risk is the risk that the Group will not be able to meet its financial obligating as they fall due.

The Group limits its liquidity risk by insuring bank facilities are available.

The table below summarizes the maturities of the Group's (undiscounted) financial liabilities as at 31 December, based on contractual payment dates and current market interest rates.

	Upon request	Less than 3 months	3 to 12 months	1 to 5 years	More than 5 years	Total
31 December 2025	JD	JD	JD	JD	JD	JD
Loan	-	-	5,845,864	1,221,000	-	7,066,864
Notes payable	-	186,337	559,011	2,276,291	-	3,021,639
Accounts payable	-	2,812,578	-	-	-	2,812,578
Total	-	2,998,915	6,404,875	3,497,291	-	12,901,081

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

	Upon request	Less than 3 months	3 to 12 months	1 to 5 years	More than 5 years	Total
31 December 2024						
Loan	-	977,499	-	-	-	977,499
Notes payable	-	180,196	540,588	2,557,188	544,371	3,822,343
Accounts payable	-	3,706,715	-	-	-	3,706,715
Total	-	4,864,410	540,588	2,557,188	544,371	8,506,557

Foreign currency risk-

The following table shows the Group's exposure to currency risk as on December 31 as a result of its financial assets and liabilities.

The table shows the effect of a reasonable possible change in the Jordanian dinar exchange rate against the following foreign currencies on the consolidated statement of profits or losses and the consolidated other comprehensive income statement, with all other variables affecting remaining constant.

	Change in the currency exchange rate against the Jordanian dinar	The effect on the profit for the year Jordanian dinar	Impact on the consolidated statement of comprehensive income and equity
2025-	(%)	JD	JD
The currency			
Tunisian dinar	10%	-	(39,287)
Eritrean nakfa	10%	(531,157)	-
Algerian dinar	10%	(1,973)	-
2024-			
The currency			
Tunisian dinar	10%	-	(39,287)
Eritrean nakfa	10%	(416,943)	-
Algerian dinar	10%	(1,973)	-

In the event that there is a negative change in the indicator, the effect is equal to the change above, while reversing the signal.

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(29) fair values

The table below analyses financial instruments carried at fair value, by valuation method. The different levels have been defined as follows:

Level 1: quoted prices (unadjusted) in active markets for financial assets.

Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices). This category includes instrument evaluated based on: Prices quoted in active markets for similar instruments or through the use of valuation model that includes inputs that can be traced to markets, these inputs could be defended directly or indirectly.

Level 3: inputs for the asset or liability that are not based on observable market data.

A- Financial assets and liabilities that are measured at fair value:

	Book value	Level 1	Level 2	Level 3
	JD	JD	JD	JD
As at 31 December 2025				
Fair value of land	7,811,833	-	7,811,833	-
Financial assets at fair value through other comprehensive income	392,869	-	-	392,869
As at 31 December 2024				
Fair value of land	7,811,833	-	7,811,833	-
Financial assets at fair value through other comprehensive income	392,869	-	-	392,869

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

B- Financial assets and liabilities that are not measured at fair value:

	As at 31 December 2025	As at 31 December 2024
	JD	JD
Book value		
Cash and bank balances	1,145,788	49,791
Due from related parties	1,278,915	2,159,804
Accounts receivable	8,761,967	12,218,694
Letters of credit under collection	135,393	90,566
Checks under collection	2,544,282	1,534,617
Murabaha financing	7,066,864	977,499
Loan and Murabaha financing	6,301,281	27,659,960
Notes payables	3,149,702	4,120,328
Due to related parties	1,282,870	1,323,111
Accounts payable	2,257,911	3,706,715

The management believes that the book value of financial assets and liabilities are not materially different from its fair value.

(30) SEGMENT INFORMATION

For management purposes, the Company is organized based on the reports which are used by the General Manager and the main Decision Maker of the Company through the geographical distribution of sales and the geographical distribution of assets and liabilities.

The geographical distribution of sales, cost of sales, gross profit and type of sold items are as follows:

<u>For the year ended 31 December 2025:</u>	Inside Jordan	Outside Jordan	Total
	JD	JD	JD
Net sales	8,279,253	15,282,829	23,562,082
Cost of sales	<u>(4,023,594)</u>	<u>(7,427,229)</u>	<u>(11,450,823)</u>
Gross profit	<u>4,255,659</u>	<u>7,855,600</u>	<u>12,111,259</u>

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

	Inside Jordan JD	Outside Jordan JD	Total JD
Other information:			
Depreciation and amortization	1,040,193	-	1,040,193
Finance costs	437,891	-	437,891
Groups' share of profit from associates	-	1,145,839	1,145,839

The geographical distribution of assets, liabilities is as follows:

	Inside Jordan JD	Outside Jordan JD	Total JD
<u>As at 31 December 2025:</u>			
Total assets	34,796,518	12,649,106	47,445,624
Total liabilities	20,424,478	2,446,728	22,871,206

	Inside Jordan JD	Outside Jordan JD	Total JD
<u>For the year 31 December 2024:</u>			
Net sales	9,292,438	7,571,852	16,864,290
Cost of sales	(5,036,230)	(4,104,447)	(9,140,677)
Gross profit	4,256,208	3,467,405	7,723,613

	Inside Jordan JD	Outside Jordan JD	Total JD
Other information:			
Depreciation and amortization	(934,573)	-	(934,573)
Finance costs	(393,095)	-	(393,095)
The group share from investment in associates	-	1,508,654	1,508,654

Assets and liabilities are allocated according to geographical locations as follows:

	Inside Jordan JD	Outside Jordan JD	Total JD
<u>As at 31 December 2024</u>			
Total assets	36,206,935	12,063,695	48,270,630
Total liabilities	40,018,696	2,627,997	42,646,693

THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
31 DECEMBER 2025

(31) CONTINGENT LIABILITY

On the date of the consolidated financial statements, the Group has a potential liability:

	<u>2025</u>	<u>2024</u>
Contingent Liability:	JD	JD
Bank guarantees	1,641,306	2,228,562
Bills of collection	216,054	277,150

Associate companies contingent liability:

The financial statements of The Jordanian Algerian Pharmaceutical Manufacturing Company (49% owned associate company) contain overdraft account issued from The Housing Bank Algeria by the amount of DZD 184.8 million as of 31 December 2025 against 100% guarantee issued from The Jordanian Pharmaceutical Manufacturing Company.

(32) LAWSUITS HELD AGAINST THE COMPANY

There are cases filed against the company for an amount of JD 195,291 as on 31 December 2025, and this is within the normal activity of the company, and in the discretion of the management and its legal advisor, the company will not have substantial obligations in response to these cases.

(33) STANDARDS ISSUED BUT NOT YET EFFECTIVE

The standards and interpretations that are issued but not yet effective, up to the date of issuance of the Group's consolidated financial statements are disclosed below. The Company intends to adopt these standards when they become effective.

IFRS 18 Presentation and Disclosure in Financial Statements

In April 2024, the IASB issued IFRS 18, which replaces IAS 1 Presentation of Financial Statements. IFRS 18 introduces new requirements for presentation within the statement of profit or loss, including specified totals and subtotals. Furthermore, entities are required to classify all income and expenses within the statement of profit or loss into one of five categories: operating, investing, financing, income taxes and discontinued operations, whereof the first three are new.

It also requires disclosure of newly defined management-defined performance measures, subtotals of income and expenses, and includes new requirements for aggregation and disaggregation of financial information based on the identified 'roles' of the primary financial statements (PFS) and the notes.

In addition, narrow-scope amendments have been made to IAS 7 Statement of Cash Flows, which include changing the starting point for determining cash flows from operations under the indirect method, from 'profit or loss' to 'operating profit or loss' and removing the optionality around classification of cash flows from dividends and interest. In addition, there are consequential amendments to several other standards.

IFRS 18, and the amendments to the other standards, is effective for reporting periods beginning on or after 1 January 2027, but earlier application is permitted and must be disclosed. IFRS 18 will apply retrospectively.

The Company is currently working to identify all impacts the amendments will have on the primary financial statements and notes to the financial statements.

IFRS 19 Subsidiaries without Public Accountability: Disclosures

In May 2024, the IASB issued IFRS 19, which allows eligible entities to elect to apply its reduced disclosure requirements while still applying the recognition, measurement and presentation requirements in other IFRS accounting standards. To be eligible, at the end of the reporting period, an entity must be a subsidiary as defined in IFRS 10, cannot have public accountability and must have a parent (ultimate or intermediate) that prepares consolidated financial statements, available for public use, which comply with IFRS accounting standards.

IFRS 19 will become effective for reporting periods beginning on or after 1 January 2027, with early application permitted.

This standard is not expected to have a material impact on the Company's financial statements.

Amendments to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture

The amendments address the conflict between IFRS 10 and IAS 28 in dealing with the loss of control of a subsidiary that is sold or contributed to an associate or joint venture. The amendments clarify that the gain or loss resulting from the sale or contribution of assets that constitute a business, as defined in IFRS 3, between an investor and its associate or joint venture, is recognised in full. Any gain or loss resulting from the sale or contribution of assets that do not constitute a business, however, is recognised only to the extent of unrelated investors' interests in the associate or joint venture.

The IASB has deferred the effective date of these amendments indefinitely, but an entity that early adopts the amendments must apply them prospectively.